Studies have identified a tumor-specific SE (PD-L1L2-SE) located between the PD-L1 and PD-L2 genes, which epigenetically co-regulates the expression of these two immune checkpoint molecules, thereby facilitating tumor immune evasion (77). Here, PDCD1LG2 is linked to neoplasm.